Skip to main content

Unable to load price data. Sorry.


22nd Cent (NYSEMKT:XXII)

CAPS Rating: No stars

Unable to load market data for this Ticker. Sorry.



This ticker is not currently Ratable.

Add Stock to CAPS Watchlist

All Players

13 Outperform
33 Underperform

All-Star Players

0 Outperform
21 Underperform

Wall Street

0 Outperform
0 Underperform

Top NYSEMKT:XXII Bull/Bear Pitches

The best Bull and Bear pitches based on recency and number of recommendations.

MightyMaven (< 20)
Submitted July 05, 2017

22nd Century Group has been beaten down due to, in my opinion, a frivolous lawsuit filed last year, half of which has been thrown out of court, the other half being moved to a different court also in NY, but in my opinion, likely to be thrown out as… More

jed71 (39.11)
Submitted December 16, 2015

The only thing this company is missing is a mini-skirt and a pair of pom poms to go with all of the cheerleading:"As we approach the end of the year, I am writing to summarize for you the many exciting developments occurring here at 22nd Century… More


Fools bullish on NYSEMKT:XXII are also bullish on:

Fools bearish on NYSEMKT:XXII are also bearish on:

Recent Community Commentary

Read the most recent pitches from players about XXII.


Member Avatar TMFSecurity (94.66) Submitted: 11/16/2021 8:32:03 AM : Underperform Start Price: $48.30 NYSE MKT:XXII Score: +109.49



Member Avatar MightyMaven (< 20) Submitted: 7/5/2017 6:01:44 PM : Outperform Start Price: $25.34 NYSE MKT:XXII Score: -211.44

22nd Century Group has been beaten down due to, in my opinion, a frivolous lawsuit filed last year, half of which has been thrown out of court, the other half being moved to a different court also in NY, but in my opinion, likely to be thrown out as well.

Numerous patents on nicotine reduction that no other company in tobacco can match and cannabinoids to the tune of over 200 patents and growing nationally and internationally.

They are already making money with sales over $10 million annually although they are mostly a research stage company. However, the list of clinical studies being done on their proprietary very low nicotine cigarettes by major universities and the National Institute of Health and other major medical entities that are showing how effective they are in reducing dependency on cigarettes and increasing the success of those who want to quit smoking is quite remarkable.

They have the right idea with their very low nicotine tobacco production increasing and they are wisely working with new and coming partners who are majors in the industry, since the tobacco is very high quality, just without the nicotine that addicts users.

They have a major disruptor in their very low nicotine cigarettes, and in their research cigarettes as well. Add to that that the FDA and the World Health Organization is calling for reduction of nicotine in cigarettes worldwide, and the reports from the FDA agencies working with XXII are on the fast track to approval. The science is not only in, it keeps coming in from university after university study. The volume of studies confirming XXII products is growing at an astounding rate. While in prior years the number of studies by NIH and major schools was under five, this year it's already near twenty ongoing studies. These are studies for the most part that are being done, being paid for, by the schools, by NIH, and not XXII, so are very very credible and very objective. They are looking at a wide range of issues in smoking cessation in these various, manifold studies.

If a person is pro-smoking, they will like the stock.
If a person is against smoking, they will like the stock.
If someone has lost someone to lung cancer, they will love it.
It's the way the tobacco industry has to go in the near and long term.

They have solid protection from all their patents.
At least one big tobacco company in invested in them.
They have a great hemp product with zero THC now gaining notice in industry circles of cannabis.

I will write an article elsewhere on MF. But this should suffice to raise interest to get you to do due diligence yourself from here.

Good luck.


Member Avatar LARBEAR1 (< 20) Submitted: 6/29/2017 10:27:55 PM : Outperform Start Price: $25.65 NYSE MKT:XXII Score: -211.12

Benifiting from bothe the tobacco industry and the need to see smoking curtailed, and the growth of the the marijuana industry and the need to increase the actual medically necessary cannabinoids of the plant.


Find the members with the highest scoring picks in XXII.

Score Leader


JoeySolitro3 (99.21) Score: +298.12

The Score Leader is the player with the highest score across all their picks in XXII.

Member Name Member
Call Time
Score Commentary
NobleOrSomeBull 99.32 1/29/2016 Underperform 5Y $19.35 -99.27% +166.22% +265.49 0 Comment
nail6891 91.42 3/11/2016 Underperform 5Y $13.65 -98.96% +154.82% +253.78 0 Comment
drexlca84 < 20 3/15/2016 Underperform 5Y $13.35 -98.94% +154.69% +253.63 0 Comment
Toprope101 97.82 5/19/2016 Underperform 5Y $11.55 -98.77% +151.38% +250.15 0 Comment
HalstedSt 92.96 4/12/2016 Underperform 5Y $11.69 -98.78% +151.13% +249.91 0 Comment
johnnyrocku 99.43 4/5/2016 Underperform 5Y $12.30 -98.84% +150.57% +249.42 0 Comment
jed71 39.11 12/16/2015 Underperform 5Y $20.75 -99.32% +149.31% +248.62 3 Comments
JoeySolitro3 99.21 4/1/2016 Underperform 5Y $11.94 -98.81% +149.15% +247.96 0 Comment
JoeySolitro1 99.95 4/1/2016 Underperform 5Y $11.92 -98.81% +149.13% +247.93 0 Comment
CancelAccount99 99.63 3/31/2016 Underperform 5Y $11.66 -98.78% +148.91% +247.69 0 Comment

Wall Street

See what the Wall Street professionals think, according to their public statements and filings.

There are no Wall Street tracker picks for XXII.